You have accessJournal of UrologyProstate Cancer: Detection and Screening1 Apr 20111907 CORRELATION OF PCA3 AND MRI WITH BIOPSY OUTCOME Gisele Leyten, Lieske Wierenga, Michiel Sedelaar, Inge van Oort, Jurgen Fütterer, Jelle Barentsz, Jack Schalken, and Peter Mulders Gisele LeytenGisele Leyten Nijmegen, Netherlands More articles by this author , Lieske WierengaLieske Wierenga Nijmegen, Netherlands More articles by this author , Michiel SedelaarMichiel Sedelaar Nijmegen, Netherlands More articles by this author , Inge van OortInge van Oort Nijmegen, Netherlands More articles by this author , Jurgen FüttererJurgen Fütterer Nijmegen, Netherlands More articles by this author , Jelle BarentszJelle Barentsz Nijmegen, Netherlands More articles by this author , Jack SchalkenJack Schalken Nijmegen, Netherlands More articles by this author , and Peter MuldersPeter Mulders Nijmegen, Netherlands More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.2045AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES PCA3 is a biomarker and MRI an imaging modality, that can be useful for predicting presence of cancer in repeat prostate biopsies. We studied the use of the Progensa® PCA3 test in a clinical academic setting. This is the first study of the combined use of PCA3 with (functional) magnetic resonance imaging (MRI) staging to predict biopsy outcome. METHODS All patients that had a Progensa® PCA3 test in the urological outpatient clinic at the Radboud University Nijmegen Medical Centre between May 2006 and December 2009 were evaluated retrospectively. The PCA3 score was correlated to clinical and pathological outcome and in a subgroup the combination with MRI was studied. The non-parametric Mann-Whitney U test and linear regression modeling were used to assess significance levels. RESULTS Data of 591 patients were analysed. A functional 3 Tesla MRI of the prostate had been performed on 163 patients. The median PCA3 score of patients with a suspicious region (SR) on MRI for prostate cancer (PCa) was significantly higher (p< 0,001) than in patients with no SR on MRI (52 vs. 21). In 50% of patients with a PCA3 score <35 there was a SR for PCa on MRI; compared to 79% in patients with a PCA3 score ≥35. This is comparable to the percentage of patients with a SR for PCa on MRI if a PCA3 cutoff score of 20 was used (43% if PCA3 <20; vs. 75% if PCA3 ≥20). In total, 290 patients underwent biopsies within 6 months after the PCA3 test. The PCA3 score was significantly correlated with Gleason score upon biopsy (p=0,001). Almost all patients (92%) with a Gleason score ≥7 upon biopsy had a PCA3 score ≥20. CONCLUSIONS Our data confirm a correlation of PCA3 with Gleason score upon biopsy. Moreover, we demonstrate that the combined use of PCA3 with MRI suspicion for prostate cancer identifies high risk cancers. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e762-e763 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gisele Leyten Nijmegen, Netherlands More articles by this author Lieske Wierenga Nijmegen, Netherlands More articles by this author Michiel Sedelaar Nijmegen, Netherlands More articles by this author Inge van Oort Nijmegen, Netherlands More articles by this author Jurgen Fütterer Nijmegen, Netherlands More articles by this author Jelle Barentsz Nijmegen, Netherlands More articles by this author Jack Schalken Nijmegen, Netherlands More articles by this author Peter Mulders Nijmegen, Netherlands More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...